NCT05827081 2026-04-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
Clinical Trials
66 trialsNCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT04423211 2026-04-03
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT04484818 2026-03-23
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT00936390 2026-03-06
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT04455750 2026-02-05
CASPAR
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03009981 2025-12-18
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Phase 3 Completed
NCT03678025 2025-09-11
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04181203 2025-07-30
CARLHA-2
UNICANCER
Phase 3 Active not recruiting
NCT02319837 2025-07-08
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT04302454 2025-04-04
ADOPT
University Medical Center Groningen
Phase 3 Active not recruiting
NCT05169112 2025-03-20
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT05440383 2025-03-14
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT01442246 2024-09-19
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
UNICANCER
Phase 3 Active not recruiting
NCT06490328 2024-07-08
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Dongkook Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting
NCT03664895 2023-12-04
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
Seoul National University Hospital
Phase 3 Unknown
NCT05781217 2023-11-18
URONCOR 06-24
Instituto de Investigación en OncologÃa Radioterápica - Fundación Española de OncologÃa Radioterápic
Phase 3 Recruiting
NCT00541047 2023-11-13
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Phase 3 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT00651326 2023-08-04
DART
Canadian Cancer Trials Group
Phase 3 Terminated
NCT04914195 2023-08-01
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Bharat Serums and Vaccines Limited
Phase 3 Completed
NCT00430183 2023-02-09
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT02914158 2023-01-17
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT02663908 2022-06-29
PRONOUNCE
Ferring Pharmaceuticals
Phase 3 Terminated
NCT00005044 2022-06-15
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT00116220 2022-01-06
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00003653 2021-06-23
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00003645 2020-04-28
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00002633 2020-04-03
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT02655237 2019-03-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Takeda
Phase 3 Completed
NCT00002597 2018-06-14
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00004635 2018-05-22
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02736435 2018-02-06
Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound
Thunder Bay Regional Health Research Institute
Phase 3 Withdrawn
NCT02980965 2017-11-13
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Phase 3 Completed
NCT00193856 2017-10-12
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00380406 2017-04-05
PROOF
Ottawa Hospital Research Institute
Phase 3 Completed
NCT01415960 2017-03-03
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
GP-Pharm
Phase 3 Completed
NCT00928434 2016-12-13
A Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00243646 2016-04-14
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Schiffler Cancer Center
Phase 3 Terminated
NCT01011751 2015-07-30
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Phase 3 Completed